Treatment when it didn’t affect albumin leakage in non-diabetic mice (Figure six). drastically reduced albumin leakage in db/db mice in comparison to automobile control remedy, even though it did not impact albumin leakage in non-diabetic mice (Figure 6).J. Mol. Sci. 2021, 22, x FOR PEER REVIEW7 of7 of7 ofInt. J. Mol. Sci. 2021, 22, 11876 nt. J. Mol. Sci. 2021, 22, x FOR PEER REVIEWFigure six. The impact of tofacitinib citrate on albumin leakage in db/db mice. Two in addition to a half months Figure six. The impact of tofacitinib citrate on albumin leakage in db/db mice. Two along with a half months Figure six. The effectdb/db and db/m miceon albumin leakage in db/db citrateTwo in addition to a for two monthsEyesdb/dbthen db/m old of tofacitinib citrate were treated with tofacitinib mice. or vehicle half weeks. old had been and old db/db and db/m mice were treated with tofacitinib citrate or car for 2 weeks. Eyes were then collected and stained for or car (red) and albumin (green). collected and stained for isolectin B4 mice have been treated with tofacitinib citrateisolectin B4for 2 weeks. Eyes had been then(A) Representative images showing (red) collected and stained for isolectin B4 (red) and albumin (green). (A) Representative photos displaying isolectin B4 and albumin in db/m and db/db mice treated with either tofacitinib citrate or car and albumin (green). (A) Representative pictures and db/db mice treated with either tofacitiniband db/db mice treated with isolectin B4 and albumin in db/m showing isolectin B4 and albumin in db/m citrate or car manage. GCL–ganglion cell layer; IPL–inner plexiform layer; INL–inner nuclear layer; nuclear either tofacitinib citrate GCL–ganglion cellGCL–ganglion cell layer; IPL–inner plexiform layer; INL–innerOPL– layer; handle. or car control. layer; IPL–inner plexiform layer; INL–inner nuclear layer; OPL– outer plexiform layer; ONL–outer nuclear Quantification of albumin albumin extravasation. Mean outer plexiform layer; ONL–outer nuclear(B)layer. (B) Quantification of extravasation. Mean SD, p 0.05, OPL–outer plexiform layer; ONL–outer nuclear layer. layer. (B) Quantification of albumin extravasation. Mean SD, p 0.05, p 0.01 by Tukeys several comparisons. SD, pANOVA followed by One particular Way ANOVA followed Tukeys various comparisons. p 0.01 by One Way 0.05, p 0.01 by A single WaysANOVA followed by by Tukey various comparisons.two.4. pJAK1 Expression in the Human the Human Diabetic Retina 2.4. pJAK1 Expression inExpression in Diabetic Retina two.four. pJAK1 the Human Diabetic Retina To understandthe prospective clinical relevance of pJAK1 as a target as a targetmanageTo realize understand the clinical relevancerelevance of pJAK1in DR manage- management, To the possible potential clinical of pJAK1 as a target in DR in DR ment, we conducted aa pilot pilottoto examine pJAK1 expressionhuman retina samples samples from ment, we performed pilota study examine pJAK1 expression in in human Aztreonam-d6 Protocol retinaretina we performed study study to examine pJAK1 expression in human samples from patients with no diabetes, diabetesdiabetes but no clinical retinopathy, and diabetes complicated from sufferers with no diabetes, diabetes but no clinical retinopathy, and diabetes complipatients with no diabetes, but no clinical retinopathy, and diabetes difficult by retinopathy. pJAK1pJAK1 was detected in 1 fourof 4 Bazedoxifene-d4 In Vitro retinas from non-diabetes donors cated by retinopathy. pJAK1 was detected in a single out out retinas from non-diabetes by retinopathy. was detected in.